	Changes in r	equirements from 2024	are highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
10	Record Type	Record ID	System generated
21	Dationt System ID Lloss	Record ID	System generated, required diagnosis year 2014 and
21	Patient System ID-Hosp NAACCR Record Version	Record ID Record ID	later. Not required for Abstract Plus users
50	NAACCR Record Version	Record ID	System generated, required diagnosis year 2014 and
60	Tumor Record Number	Record ID	later. Not required for Abstract Plus users
70	Addr at DXCity	Demographic	
80	Addr at DXState	Demographic	
90	County at DX Reported	Demographic	
100	Addr at DXPostal Code	Demographic	
102	Addr at DXCountry	Demographic	
150	Marital Status at DX	Demographic	
160	Race 1	Demographic	Primary race code for all diagnosis years
161	Race 2	Demographic	Diagnosis year 2000 and later
162	Race 3	Demographic	Diagnosis year 2000 and later
163	Race 4	Demographic	Diagnosis year 2000 and later
164	Race 5	Demographic	Diagnosis year 2000 and later
190	Spanish/Hispanic Origin	Demographic	
220	Sex	Demographic	
230	Age at Diagnosis	Demographic	Calculated from Date of Birth and Date of Diagnosis
230	Age at Diagnosis	Demographic	Calculated from Date of Birth and Date of Diagnosis
240	Date of Birth	Demographic	
252	BirthplaceState	Demographic	
254	BirthplaceCountry	Demographic	
	, ,		Diagnosis year 2022 and later, required when
344	Tobacco Use Smoking Status	Demographic	available
390	Date of Diagnosis	Cancer Identification	
400	Primary Site	Cancer Identification	
410	Laterality	Cancer Identification	
440	Grade	Cancer Identification	Required through diagnosis year 2017
490	Diagnostic Confirmation	Cancer Identification	
500	Type of Reporting Source	Cancer Identification	
501	Casefinding Source	Cancer Identification	Diagnosis year 2006 and later
522	Histologic Type ICD-O-3	Cancer Identification	Diagnosis year 2001 and later
523	Behavior Code ICD-O-3	Cancer Identification	Diagnosis year 2001 and later
540	Reporting Facility	Hospital-Specific	
545	NPIReporting Facility	Hospital-Specific	Diagnosis year 2007 and later as available
550	Accession NumberHosp	Hospital-Specific	Not required for Abstract Plus users.
560	Sequence NumberHospital	Hospital-Specific	
570	Abstracted By	Hospital-Specific	For abstracts with Date Case Initiated 1/1/2014 and later, the state assigned Abstractor ID must be used
580	Date of 1st Contact	Hospital-Specific	

	Changes in re	equirements from 2024 a	re highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
610	Class of Case	Hospital-Specific	
630	Primary Payer at DX	Hospital-Specific	Diagnosis year 2006 and later
670	RX HospSurg Prim Site 03-2022	Hospital-Specific	Diagnosis year 2003 - 2022
671	RX HospSurg Prim Site 2023	Hospital-Specific	Diagnosis year 2023 and later
672	RX HospScope Reg LN Sur	Hospital-Specific	
674	RX HospSurg Oth Reg/Dis	Hospital-Specific	
	Date Regional Lymph Node		
682	Dissection	Stage/Prognostic Factors	Diagnosis year 2018 and later
700	RX HospChemo	Hospital-Specific	
710	RX HospHormone	Hospital-Specific	
720	RX HospBRM	Hospital-Specific	
730	RX HospOther	Hospital-Specific	
751	RX Hosp-Recon Breast	Hospital-Specific	Diagnosis year 2024 and later
752	Tumor Size Clinical	Stage/Prognostic Factors	Diagnosis year 2016 - 2023
754	Tumor Size Pathologic	Stage/Prognostic Factors	Diagnosis year 2016 - 2023
756	Tumor Size Summary	Stage/Prognostic Factors	Diagnosis year 2016 and later
759	SEER Summary Stage 2000	Stage/Prognostic Factors	Diagnosis year 2001-2003 and 2015-2017
764	Summary Stage 2018	Stage/Prognostic Factors	Diagnosis year 2018 and later
772	EOD Primary Tumor	Stage/Prognostic Factors	Diagnosis year 2018 and later
774	EOD Regional Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later
776	EOD Mets	Stage/Prognostic Factors	Diagnosis year 2018 and later
820	Regional Nodes Positive	Stage/Prognostic Factors	Diagnosis year 1999 and later
830	Regional Nodes Examined	Stage/Prognostic Factors	Diagnosis year 1999 and later
	Date of Sentinel Lymph Node		Diagnosis year 2018 and later, Required when
832	Biopsy	Stage/Prognostic Factors	available (Breast and Melanoma of Skin)
834	Sentinel Lymph Nodes Examined	Stage/Prognostic Factors	Diagnosis year 2018 and later (Breast and Melanoma of Skin)
835	Sentinel Lymph Nodes Positive	Stage/Prognostic Factors	Diagnosis year 2018 and later (Breast and Melanoma of Skin)
880	TNM Path T	Stage/Prognostic Factors	
890	TNM Path N	Stage/Prognostic Factors	AJCC TNM 7th Edition:
900	TNM Path M	Stage/Prognostic Factors	Diagnosis year 2015:
910	TNM Path Stage Group	Stage/Prognostic Factors	Required for CoC-accredited hospitals
920	TNM Path Descriptor	Stage/Prognostic Factors	Required, when available for other
930	TNM Path Staged By	Stage/Prognostic Factors	reporting facilities
940	TNM Clin T	Stage/Prognostic Factors	
950	TNM Clin N	Stage/Prognostic Factors	Diagnosis year 2016 and 2017:
960	TNM Clin M	Stage/Prognostic Factors	Required for all reporting facilities
970	TNM Clin Stage Group	Stage/Prognostic Factors	
980	TNM Clin Descriptor	Stage/Prognostic Factors	
990	TNM Clin Staged By	Stage/Prognostic Factors	
1060	TNM Edition Number	Stage/Prognostic Factors	Diagnosis year 2016 and 2017
1068	Grade Post Therapy Clin (yc)	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
1112	Mets at DX-Bone	Stage/Prognostic Factors	Diagnosis year 2016 and later
1112	Mets at DX-Brain	Stage/Prognostic Factors	Diagnosis year 2016 and later
1113	Mets at Dx-Distant LN		Diagnosis year 2016 and later
****		Stage/Prognostic Factors	

	Changes in re	quirements from 2024 a	re highlighted in yellow.
NAACCR			
Item #	NAACCR Item Name	Section	Comment
1115	Mets at DX-Liver	Stage/Prognostic Factors	Diagnosis year 2016 and later
1116	Mets at DX-Lung	Stage/Prognostic Factors	Diagnosis year 2016 and later
1117	Mets at DX-Other	Stage/Prognostic Factors	Diagnosis year 2016 and later
	Post Transplant		
1172		Stage/Prognostic Factors	Diagnosis year 2025 and later schema-specific
1174	PD-L1	Stage/Prognostic Factors	Diagnosis year 2025 and later schema-specific
1182	Lymphovascular Invasion	Stage/Prognostic Factors	Diagnosis year 2010 and later
1200	RX Date Surgery	Treatment-1st Course	
1210	RX Date Radiation	Treatment-1st Course	
1220	RX Date Chemo	Treatment-1st Course	
1230	RX Date Hormone	Treatment-1st Course	
1240	RX Date BRM	Treatment-1st Course	
1250	RX Date Other	Treatment-1st Course	
1260	Date Initial RX SEER	Treatment-1st Course	
1270	Date 1st Crs RX CoC	Treatment-1st Course	
1285	RX SummTreatment Status	Treatment-1st Course	Diagnosis year 2010 and later
1290	RX SummSurg Prim Site 03-2022	Treatment-1st Course	Diagnosis year 2003 - 2022
1291	RX SummSurg Prim Site 2023	Treatment-1st Course	Diagnosis year 2023 and later
1292	RX SummScope Reg LN Sur	Treatment-1st Course	Diagnosis year 2003 and later
1294	RX SummSurg Oth Reg/Dis	Treatment-1st Course	Diagnosis year 2003 and later
1320	RX SummSurgical Margins	Treatment-1st Course	Required, when available
1335	RX SummRecon Breast	Treatment-1st Course	Diagnosis year 2024 and later
1340	Reason for No Surgery	Treatment-1st Course	
1360	RX SummRadiation	Treatment-1st Course	Required through diagnosis year 2017
1380	RX SummSurg/Rad Seq	Treatment-1st Course	
1390	RX SummChemo	Treatment-1st Course	
1400	RX SummHormone	Treatment-1st Course	
1410	RX SummBRM	Treatment-1st Course	
1420	RX SummOther	Treatment-1st Course	
1430	Reason for No Radiation	Treatment-1st Course	
1501	Phase I Dose per Fraction	Treatment-1st Course	Required, when available
	Phase I Radiation External Beam		
1502	Planning Tech	Treatment-1st Course	Required, when available
1503	Phase I Number of Fractions	Treatment-1st Course	Required, when available
	Phase I Radiation Primary		
1504	Treatment Volume	Treatment-1st Course	Required, when available
	Phase I Radiation to Draining		
1505	Lymph Nodes	Treatment-1st Course	Required, when available
	Phase I Radiation Treatment		
1506	Modality	Treatment-1st Course	Required
1507	Phase I Total Dose	Treatment-1st Course	Required, when available
1511	Phase II Dose per Fraction	Treatment-1st Course	Required, when available
	Phase II Radiation External Beam		
1512	Planning Tech	Treatment-1st Course	Required, when available
1513	Phase II Number of Fractions	Treatment-1st Course	Required, when available

	Changes in re	quirements from 2024 are	highlighted in yellow.
NAACCR	NAACCR Item Name	Section	Commont
ltem #	Phase II Radiation Primary	Section	Comment
1514	Treatment Volume	Treatment-1st Course	Required, when available
1914	Phase II Radiation to Draining		
1515	Lymph Nodes	Treatment-1st Course	Required, when available
	Phase II Radiation Treatment		
1516	Modality	Treatment-1st Course	Required
1517	Phase II Total Dose	Treatment-1st Course	Required, when available
1521	Phase III Dose per Fraction	Treatment-1st Course	Required, when available
	Phase III Radiation External Beam		
1522	Planning Tech	Treatment-1st Course	Required, when available
1523	Phase III Number of Fractions	Treatment-1st Course	Required, when available
	Phase III Radiation Primary		
1524	Treatment Volume	Treatment-1st Course	Required, when available
	Phase III Radiation to Draining		
1525	Lymph Nodes	Treatment-1st Course	Required, when available
	Phase III Radiation Treatment		
1526	Modality	Treatment-1st Course	Required
1527	Phase III Total Dose	Treatment-1st Course	Required, when available
	Radiation Treatment		
1531	Discontinued Early	Treatment-1st Course	Required, when available
	Number of Phases of Rad		
1532	Treatment to this Volume	Treatment-1st Course	Required, when available
1533	Total Dose	Treatment-1st Course	Required, when available
			Diagnosis year 2006-2011 all cases, 2012-2014 site-
1570	RadRegional RX Modality	Treatment-1st Course	specific, and 2015-2017 all cases
1632	Neoadjuvant Therapy	Treatment-1st Course	Diagnosis year 2021 and later
	Neoadjuvant Therapy-Clinical		
1633	Response	Treatment-1st Course	Diagnosis year 2021 and later
	Neoadjuvant Therapy-Treatment		
1634	Effect	Treatment-1st Course	Diagnosis year 2021 and later
1639	RX SummSystemic/Sur Seq	Treatment-1st Course	Diagnosis year 2006 and later
1750	Date of Last Contact	Follow-up/Recurrence/Death	
1760	Vital Status	Follow-up/Recurrence/Death	
			Diagnosis year 2022 and later, required when
1770	Cancer Status	Follow-up/Recurrence/Death	available
4772	Date of Last Cancer (tumor)		Diagnosis year 2022 and later, required when
1772	Status	Follow-up/Recurrence/Death	available
1810	Addr CurrentCity	Follow-up/Recurrence/Death	Diagnosis year 2013 and later
1820	Addr Current-State	Follow-up/Recurrence/Death	Diagnosis year 2013 and later
1830	Addr CurrentPostal Code	Follow-up/Recurrence/Death	Diagnosis year 2013 and later
1832	Addr CurrentCountry	Demographic	Diagnosis year 2013 and later Diagnosis year 2013 and later, required when
1000	Desurrance Data 1st	Follow-up/Recurrence/Death	
1860	Recurrence Date1st	Follow-up/Recurrence/Death	available
1880	Recurrence Type 1st	Follow-up/Recurrence/Death	Diagnosis year 2013 and later, required when available
1880	Recurrence Type1st Place of DeathState	Demographic	Required, when available
1942 1944	Place of DeathState	Demographic	Required, when available Required, when available
1944 1981-		Edit Overrides/ Conversion	ווכקטווכט, איווכוו מימוומטופ
		Lait Overhues/ COnversion	

	Changes in r	equirements from 2024 are	e highlighted in yellow.
NAACCR	NAACCR Item Name	Section	Comment
Item #	NAACCK Item Name	Edit Overrides/ Conversion	Comment
2085	Date Case Initiated	History/ System Admin	System generated
2065	Date Case Initiated	Edit Overrides/ Conversion	System generated
2110	Date Case Report Exported	History/ System Admin	System generated
2110	Date case Report Exported	Edit Overrides/ Conversion	System generated
2117	Schema ID Version Current	History/ System Admin	System generated
2117		Edit Overrides/ Conversion	System generated
2118	Schema ID Version Original	History/ System Admin	System generated
2110		Edit Overrides/ Conversion	System generated
2152	CoC Accredited Flag	History/ System Admin	System generated
2132	AJCC Cancer Surveillance DLL	Edit Overrides/ Conversion	System generated
2158	Version Current	History/ System Admin	System generated
2130	AJCC Cancer Surveillance DLL	Edit Overrides/ Conversion	System generated
2150	Version Original	History/ System Admin	System generated
2159		Edit Overrides/ Conversion	System generated
2170	Vendor Name	History/ System Admin	
2230	NameLast	Patient-Confidential	
2230	NameBirth Surname	Patient-Confidential	
	NameFirst	Patient-Confidential	
2240	NameMiddle	Patient-Confidential	
2250			
2270	NameSuffix	Patient-Confidential	
2280	NameAlias	Patient-Confidential	
2290	NameSpouse/Parent	Patient-Confidential	
2300	Medical Record Number	Patient-Confidential	
2320	Social Security Number	Patient-Confidential	
2330	Addr at DXNo & Street	Patient-Confidential	
2335	Addr at DXSupplementl	Patient-Confidential	
2350	Addr CurrentNo & Street	Patient-Confidential	Diagnosis year 2013 and later
2355	Addr CurrentSupplementl	Patient-Confidential	Diagnosis year 2013 and later
2360	Telephone	Patient-Confidential	
2415	NPIInst Referred From	Hospital-Confidential	Diagnosis year 2007 and later as available
2425	NPIInst Referred To	Hospital-Confidential	Diagnosis year 2007 and later as available
2460	PhysicianManaging	Other-Confidential	The NPI is the preferred ID number for collection. If
2465	NPIPhysicianManaging	Other-Confidential	NPIPhysicianManaging is blank, Physician Managing cannot be blank.
2470	PhysicianFollow-Up	Other-Confidential	The NPI is the preferred ID number for collection. If NPIPhysicianFollow-Up is blank, PhysicianFollow-
2475	NPIPhysicianFollow-Up	Other-Confidential	up cannot be blank.
			The NPI is the preferred ID number for collection.lf
			NPIPhysicianPrimary Surg is blank, Physician
2480	PhysicianPrimary Surg	Other-Confidential	Primary Surg cannot be blank. <u>Exception</u> : if surgery
			of primary site codes indicate surgery was not done,
			NPIPhysicianPrimary Surg and Physician Primary
2485	NPIPhysicianPrimary Surg	Other-Confidential	Surg may both be blank.
			The NPI is the preferred ID number for collection.
2400	Dhusisian 2	Othen Confidential	NPIPhysician 3 or Physician 3 are Required, when
2490	Physician 3	Other-Confidential	available.
2495	NPIPhysician 3	Other-Confidential	

	Changes in requirements from 2024 are highlighted in yellow.			
NAACCR Item #	NAACCR Item Name	Section	Comment	
2500	Physician 4	Other-Confidential	The NPI is the preferred ID number for collection. NPIPhysician 4 or Physician 4 are Required, when	
2505	NPIPhysician 4	Other-Confidential	available.	
2520	TextDX ProcPE	Text-Diagnosis		
2530	TextDX ProcX-ray/Scan	Text-Diagnosis		
2540	TextDX ProcScopes	Text-Diagnosis		
2550	TextDX ProcLab Tests	Text-Diagnosis		
2560	TextDX ProcOp	Text-Diagnosis		
2570	TextDX ProcPath	Text-Diagnosis		
2580	TextPrimary Site Title	Text-Diagnosis		
2590	TextHistology Title	Text-Diagnosis	There MUST be text to support coding of data fields in the cancer identification, stage and treatment	
2600	TextStaging	Text-Diagnosis	sections of the abstract.	
2610	RX TextSurgery	Text-Treatment		
2620	RX TextRadiation (Beam)	Text-Treatment		
2630	RX TextRadiation Other	Text-Treatment		
2640	RX TextChemo	Text-Treatment		
2650	RX TextHormone	Text-Treatment		
2660	RX TextBRM	Text-Treatment		
2670	RX TextOther	Text-Treatment		
2680	TextRemarks	Text-Miscellaneous	Additional text or overflow from other text fields	
2690	TextPlace of Diagnosis	Text-Miscellaneous	Text about facility, physician office, city, state, or county where the diagnosis was made.	
2800	CS Tumor Size	Stage/Prognostic Factors	Diagnosis year 2004-2017	
2810	CS Extension	Stage/Prognostic Factors	Diagnosis year 2004-2017	
2820	CS Tumor Size/Ext Eval	Stage/Prognostic Factors	Diagnosis year 2004-2017	
2830	CS Lymph Nodes	Stage/Prognostic Factors	Diagnosis year 2004-2017	
2840	CS Lymph Nodes Eval	Stage/Prognostic Factors	Diagnosis year 2004-2017	
2850	CS Mets at DX	Stage/Prognostic Factors	Diagnosis year 2004-2017	
2851	CS Mets at DX-Bone	Stage/Prognostic Factors	Diagnosis year 2010-2015	
2852	CS Mets at DX-Brain	Stage/Prognostic Factors	Diagnosis year 2010-2015	
2853	CS Mets at DX-Liver	Stage/Prognostic Factors	Diagnosis year 2010-2015	
2854	CS Mets at DX-Lung	Stage/Prognostic Factors	Diagnosis year 2010-2015	
2860	CS Mets Eval	Stage/Prognostic Factors	Diagnosis year 2004-2017	

	Changes in I	requirements from 2024 are	highlighted in yellow.
NAACCR		Castian	Comment
Item #	NAACCR Item Name	Section	Comment
2861	CS Site-Specific Factor 7	Stage/Prognostic Factors	
2862	CS Site-Specific Factor 8	Stage/Prognostic Factors	
2863	CS Site-Specific Factor 9	Stage/Prognostic Factors	-
2864	CS Site-Specific Factor10	Stage/Prognostic Factors	
2865	CS Site-Specific Factor11	Stage/Prognostic Factors	-
2866	CS Site-Specific Factor12	Stage/Prognostic Factors	-
2867	CS Site-Specific Factor13	Stage/Prognostic Factors	Diagnosis year 2004-2017
2868	CS Site-Specific Factor14	Stage/Prognostic Factors	For CS Site-Specific Factor
2869	CS Site-Specific Factor15	Stage/Prognostic Factors	coding requirements, see the
2870	CS Site-Specific Factor16	Stage/Prognostic Factors	NCI-SEER website:
2871	CS Site-Specific Factor17	Stage/Prognostic Factors	
2872	CS Site-Specific Factor18	Stage/Prognostic Factors	
2873	CS Site-Specific Factor19	Stage/Prognostic Factors	Required Factors
2874	CS Site-Specific Factor20	Stage/Prognostic Factors	SEER, Version 0205
2875	CS Site-Specific Factor21	Stage/Prognostic Factors	
2876	CS Site-Specific Factor22	Stage/Prognostic Factors	
2877	CS Site-Specific Factor23	Stage/Prognostic Factors	
2878	CS Site-Specific Factor24	Stage/Prognostic Factors	http://seer.cancer.gov/csreqstatus/application.html
2879	CS Site-Specific Factor25	Stage/Prognostic Factors	?report=requiredFactors&setter=seer&version=0205
2880	CS Site-Specific Factor 1	Stage/Prognostic Factors	<u>&schema=0&years=0</u>
2890	CS Site-Specific Factor 2	Stage/Prognostic Factors	
2900	CS Site-Specific Factor 3	Stage/Prognostic Factors	-
2910	CS Site-Specific Factor 4	Stage/Prognostic Factors	-
2920	CS Site-Specific Factor 5	Stage/Prognostic Factors	-
2930	CS Site-Specific Factor 6	Stage/Prognostic Factors	-
2935	CS Version Input Original	Stage/Prognostic Factors	Diagnosis year 2004-2017
2936	CS Version Derived	Stage/Prognostic Factors	Diagnosis year 2004-2017
2937	CS Version Input Current	Stage/Prognostic Factors	Diagnosis year 2004-2017
2940	Derived AJCC-6 T	Stage/Prognostic Factors	Diagnosis year 2004-2017
2950	Derived AJCC-6 T Descript	Stage/Prognostic Factors	Diagnosis year 2004-2017
2960	Derived AJCC-6 N	Stage/Prognostic Factors	Diagnosis year 2004-2017
2970	Derived AJCC-6 N Descript	Stage/Prognostic Factors	Diagnosis year 2004-2017
2980	Derived AJCC-6 M	Stage/Prognostic Factors	Diagnosis year 2004-2017
2990	Derived AJCC-6 M Descript	Stage/Prognostic Factors	Diagnosis year 2004-2017
3000	Derived AJCC-6 Stage Grp	Stage/Prognostic Factors	Diagnosis year 2004-2017
3010	Derived SS1977	Stage/Prognostic Factors	Diagnosis year 2004-2017
3020	Derived SS2000	Stage/Prognostic Factors	Diagnosis year 2004-2017
3030	Derived AJCCFlag	Stage/Prognostic Factors	Diagnosis year 2004-2017
3040	Derived SS1977Flag	Stage/Prognostic Factors	Diagnosis year 2004-2017
3050	Derived SS2000Flag	Stage/Prognostic Factors	Diagnosis year 2004-2017
3170	RX Date Mst Defn Srg	Treatment-1st Course	Diagnosis year 2015 and later
3230	RX Date Systemic	Treatment-1st Course	
3250	RX SummTransplnt/Endocr	Treatment-1st Course	
3400	Derived AJCC-7 T	Stage/Prognostic Factors	Diagnosis year 2010-2017
3402	Derived AJCC-7 T Descript	Stage/Prognostic Factors	Diagnosis year 2010-2017
3410	Derived AJCC-7 N	Stage/Prognostic Factors	Diagnosis year 2010-2017 Diagnosis year 2010-2017
3412	Derived AJCC-7 N Descript		Diagnosis year 2010-2017 Diagnosis year 2010-2017
3412	beinea Alee-7 is Descript	Stage/Prognostic Factors	Diagnosis year 2010-2017

	Changes in re	quirements from 2024 ar	e highlighted in yellow.
NAACCR			
ltem #	NAACCR Item Name	Section	Comment
3420	Derived AJCC-7 M	Stage/Prognostic Factors	Diagnosis year 2010-2017
3422	Derived AJCC-7 M Descript	Stage/Prognostic Factors	Diagnosis year 2010-2017
3430	Derived AJCC-7 Stage Grp	Stage/Prognostic Factors	Diagnosis year 2010-2017
3700	SEER Site-Specific Fact 1	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3780-			
3798	Secondary Diagnosis 1-10	Stage/Prognostic Factors	Required, when available
3800	Schema ID	Stage/Prognostic Factors	System generated
	Chromosome 1p: Loss of		
3801	Heterozygosity (LOH)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Chromosome 19q: Loss of		
3802	Heterozygosity (LOH)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3803	Adenoid Cystic Basaloid Pattern	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3804	Adenopathy	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
5004		Stage/Trognostie Factors	
3805	AFP Post-Orchiectomy Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3806	AFP Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3800	AFP Pre-Orchiectomy Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3808	AFP Pre-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
5000	Art Tre-Oremeetonry Nange	Stage/Prognostic Factors	Diagnosis year 2010 and later schema specific
3809	AFP Pretreatment Interpretation	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3810	AFP Pretreatment Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3811	Anemia	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3812	B symptoms	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
0012	Bilirubin Pretreatment Total Lab		
3813	Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
0010	Bilirubin Pretreatment Unit of		
3814	Measure	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3815	Bone Invasion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3816	Brain Molecular Markers	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3817	Breslow Tumor Thickness	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3017	CA-125 Pretreatment		
3818	Interpretation	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3819	CEA Pretreatment Interpretation	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3820	CEA Pretreatment Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3821	Chromosome 3 Status	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3822	Chromosome 8q Status	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Circumferential Resection Margin		
3823	(CRM)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
0010	Creatinine Pretreatment Lab		
3824	Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Creatinine Pretreatment Unit of		
3825	Measure	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Estrogen Receptor Percent		
3826	Positive or Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3827	Estrogen Receptor Summary	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Estrogen Receptor Total Allred		,

	Changes in re	quirements from 2024 are	highlighted in yellow.
NAACCR	NAACCE Itom Name	Section	Comment
ltem #	Esophagus and EGJ Tumor	Section	Comment
3829	Epicenter	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3029	Extranodal Extension Clin (non-	Stage/Flogilostic Factors	Diagnosis year 2010 and later schema specific
3830	Head and Neck)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3830	Extranodal Extension Head and	Stage/Froghostic Factors	Diagnosis year 2010 and later schema specifie
3831	Neck Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
5051	Extranodal Extension Head and		
3832	Neck Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
0001	Extranodal Extension Path (non-		
3833	Head and Neck)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3834	Extravascular Matrix Patterns	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3835	Fibrosis Score	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3836	FIGO Stage	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Gestational Trophoblastic		
3837	Prognostic Scoring Index	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3838	Gleason Patterns Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3839	Gleason Patterns Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3840	Gleason Score Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3841	Gleason Score Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3842	Gleason Tertiary Pattern	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3843	Grade Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later
3844	Grade Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later
3845	Grade Post Therapy Path (yp)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3846	hCG Post-Orchiectomy Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3847	hCG Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3848	hCG Pre-Orchiectomy Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3849	hCG Pre-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3855	HER2 Overall Summary	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3856	Heritable Trait	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3857	High Risk Cytogenetics	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3858	High Risk Histologic Features	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3859	HIV Status International Normalized Ratio	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2000			Diagnosis year 2019 and later scheme specific
3860	Prothrombin Time Ipsilateral Adrenal Gland	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2001	Involvement		Diagnosis year 2018 and later schema-specific
3861	JAK2	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3862	Ki-67	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3863	Invasion Beyond Capsule	Stage/Prognostic Factors Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3864		Stage/Prognostic Factors	Diagnosis year 2010 and later schema specific
3865	KIT Gene Immunohistochemistry	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3866	KRAS	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3867	LDH Post-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3868	LDH Pre-Orchiectomy Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3869	LDH Level	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3870	LDH Upper Limits of Normal	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3871	LN Assessment Method Femoral- Inguinal	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific

	Changes in re	quirements from 2024 are h	nighlighted in yellow.
NAACCR	NAACCR Item Name	Section	Comment
Item #	LN Assessment Method Para-	Section	Comment
3872	Aortic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3873	LN Assessment Method Pelvic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3874	LN Distant Assessment Method	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3875	LN Distant: Mediastinal Scalene	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3876	LN Head and Neck Levels I-III	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3877	LN Head and Neck Levels IV-V	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3878	LN Head and Neck Levels VI-VII	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3879	LN Head and Neck Other	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3880	LN Isolated Tumor Cells (ITC)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3881	LN Laterality	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3882	LN Positive Axillary Level I-II	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3883	LN Size	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3885	Lymphocytosis	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3886	Major Vein Involvement	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3887	Measured Basal Diameter	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3888	Measured Thickness	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Methylation of O6-Methylguanine		
3889	Methyltransferase	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3890	Microsatellite Instability (MSI)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3891	Microvascular Density	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3892	Mitotic Count Uveal Melanoma	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3893	Mitotic Rate Melanoma	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3894	Multigene Signature Method	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3895	Multigene Signature Results	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	NCCN International Prognostic		
3896	Index (IPI)	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3897	Number of Cores Examined	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3898	Number of Cores Positive	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Number of Examined Para-Aortic		
3899	Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Number of Examined Pelvic		
3900	Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Number of Positive Para-Aortic		
3901	Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3902	Number of Positive Pelvic Nodes	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Oncotype Dx Recurrence Score-		
3903	DCIS	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Oncotype Dx Recurrence Score-		
3904	Invasive	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3905	Oncotype Dx Risk Level-DCIS	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2006	Oncotype Dx Risk Level-Invasive	Stage/Prognostic Easters	Diagnosis year 2018 and later schema-specific
3906 3907	Organomegaly	Stage/Prognostic Factors Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3507	S. Burrellerary	Juager Frogrostic Factors	

	Changes in re	quirements from 2024 are	highlighted in yellow.
NAACCR		Castian	Comment
ltem #	NAACCR Item Name	Section	Comment
2000	Percent Necrosis Post		Diagnosis year 2018 and later scheme specific
3908	Neoadjuvant	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3909	Perineural Invasion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3910	Peripheral Blood Involvement	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3911	Peritoneal Cytology	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3913	Pleural Effusion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Progesterone Receptor Percent		
3914	Positive or Range	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3915	Progesterone Receptor Summary	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Progesterone Receptor Total		
3916	Allred Score	Stage/Prognostic Factors	Diagnosis year 2018 - 2022 schema-specific
3918	Profound Immune Suppression EOD Prostate Pathologic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2040	Extension		Diagnosis year 2018 and later scheme specific
3919		Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2020	PSA (Prostatic Specific Antigen) Lab Value		Diagnosis year 2018 and later scheme specific
3920	Residual Tumor Volume Post	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2024			Diagnosis year 2018 and later schema-specific
3921	Cytoreduction Response to Neoadjuvant	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2022	Therapy		Diagnosis year 2018 and later schema-specific
3922	S Category Clinical	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3923		Stage/Prognostic Factors	
3924	S Category Pathological	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3925	Sarcomatoid Features	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3926	Schema Discriminator 1	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3927	Schema Discriminator 2	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3928	Schema Discriminator 3	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3929	Separate Tumor Nodules	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Serum Albumin Pretreatment		Diagnosis year 2018 and later schema-specific
3930	Level	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
2024	Serum Beta-2 Microglobulin		Diagnosis year 2018 and later scheme specific
3931	Pretreatment Level	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3932	LDH Lab Value	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3933	Thrombocytopenia	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3934	Tumor Deposits	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3936	Ulceration	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
	Visceral and Parietal Pleural		Diagnosis was a 2018 and later ashows an acidia
3937	Invasion	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific
3938	ALK Rearrangement	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
3939	EGFR Mutational Analysis	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
3940	BRAF Mutational Analysis	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
3941	NRAS Mutational Analysis	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
3942	CA 19-9 PreTX Lab Value	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific
3943	NCDBSARSCoV2Test	Special Use	Required when available through diagnosis year 2022
5343			Required when available through diagnosis year
3944	NCDBSARSCoV2Pos	Special Use	2022
	NCDBSARSCoV2Pos Date	Special Use	Required when available through diagnosis year 2022

	Changes in requirements from 2024 are highlighted in yellow.			
NAACCR Item #	NAACCR Item Name	Section	Comment	
			Required when available through diagnosis year	
3946	NCDBCOVID19Tx Impact	Special Use	2022	
	Macroscopic Evaluation of			
3950	Mesorectum	Stage/Prognostic Factors	Diagnosis year 2022 and later schema-specific	
3956	p16	Stage/Prognostic Factors	Diagnosis year 2021 and later schema-specific	
3957	LN Status Pelvic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3958	LN Status Para-Aortic	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3959	LN Status Femoral-Inguinal	Stage/Prognostic Factors	Diagnosis year 2018 and later schema-specific	
3960	Histologic Subtype	Stage/Prognostic Factors	Diagnosis year 2023 and later schema-specific	
3961	Clinical Margin Width	Stage/Prognostic Factors	Diagnosis year 2023 and later schema-specific	
3964	Brain Primary Tumor Location	Stage/Prognostic Factors	Diagnosis year 2024 and later schema-specific	
7090	Path Report Number 1	Pathology	Required, when available	

In addition to the data items specified in the required data set, Georgia accepts and would like to receive all data items collected by CoC-accredited programs in our state as part of regular monthly submissions.